A Pharmacokinetic Study of Intravenous CTLA4Ig, a Novel Immunosuppressive Agent, in Mice

@article{Srinivas1996APS,
  title={A Pharmacokinetic Study of Intravenous CTLA4Ig, a Novel Immunosuppressive Agent, in Mice},
  author={N. Srinivas and R. Weiner and W. Shyu and J. Calore and D. Tritschler and L. Tay and J. Lee and D. Greene and R. Barbhaiya},
  journal={Journal of Pharmaceutical Sciences},
  year={1996},
  volume={85},
  pages={296-298}
}
Abstract Three skin-intact mice in each group received a single 0.07-, 0.29-, or 0.57-mg dose of CTLA4Ig intravenously (iv). Three skin-grafted mice received a single 0.29-mg dose iv and another three skin-grafted mice received a 0.29-mg dose once daily for 7 days (the dose was administered via the tail vein). Serial blood samples (0.15 mL) were obtained by retro-orbital bleeds up to 240 h after all single doses and up to 360 h after the last multiple dose. Serum samples were analyzed for… Expand
View via Publisher
7 Citations
Background Citations
2

7 Citations

Citation Type

Citation Type

Pharmacokinetics and pharmacodynamics of CTLA4lg (BMS-188667), a novel immunosuppressive agent, in monkeys following multiple doses.
  • 16
Assessment of Dose Proportionality, Absolute Bioavailability, and Immunogenicity Response of CTLA4Ig (BMS-188667), a Novel Immunosuppressive Agent, Following Subcutaneous and Intravenous Administration to Rats
  • 11
Population Pharmacokinetics and Pharmacodynamics of the Anti-CD11a Antibody hu1124 in Human Subjects with Psoriasis
  • 127
Local gene therapy with CTLA4‐immunoglobulin fusion protein in experimental allergic encephalomyelitis
  • 54
CTLA4-Ig fusion proteins: promise for improved therapy of transplant rejection and autoimmune diseases
  • 1
Late blockade of T cell costimulation interrupts progression of experimental chronic allograft rejection.
  • 127
  • PDF
Prediction of human clearance of therapeutic proteins: simple allometric scaling method revisited
  • 76

References

SHOWING 1-10 OF 11 REFERENCES
Interference with cyclophosphamide-induced skin allograft tolerance by cyclosporin A.
  • 48
CTLA4Ig prolongs allograft survival while suppressing cell-mediated immunity.
  • 111
Cyclosporin A and FK506: molecular mechanisms of immunosuppression and probes for transplantation biology.
  • 166
Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4lg.
  • 1,148
The role of the CD28 receptor during T cell responses to antigen.
  • 1,341
T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo.
  • L. Turka, P. Linsley, +7 authors D. Gordon
  • Biology, Medicine
  • Proceedings of the National Academy of Sciences of the United States of America
  • 1992
  • 551
  • PDF
A cell culture model for T lymphocyte clonal anergy.
  • 1,971
Applied regression analysis (2. ed.)
  • N. Draper, H. Smith
  • Computer Science
  • Wiley series in probability and mathematical statistics
  • 1981
  • 3,267
Review of CTLA4Ig use for allograft immunosuppression.
  • 18
Tolerance induction by soluble CTLA4 in a mouse skin transplant model.
  • 20
...
1
2
...